ClinicalTrials.gg
RecruitingNCT06078215CERBERUSUpdated Oct 13, 2023

CERebrolysine Effect on Blood-brain Barrier in acUte Ischemic Stroke

A Phase 4 interventional study of Cerebrolysin in Acute Ischemic Stroke, sponsored by Poznan University of Medical Sciences. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-10-13.

Sponsored by Poznan University of Medical Sciences · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Registered 8 months after the study started (first participant enrolled Jan 2023, registered Oct 2023).
  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
350
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing cerebrolysin in Ischemic Stroke — 5 open to participants now, 5 under way, none of them phase 3. cerebrolysin · Ischemic Stroke.

Planned enrollment
3rd of 12
350 · median 92
Started
2023
with 1 other
Phase 4
4 of 12
2 open now
Registered
9th of 12
by date
Lead sponsor
1 of 12
Poznan University of Medical Sciences

Among the 12 studies testing cerebrolysin in Ischemic Stroke, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2023, is one of 4 in phase 4, and was the 9th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

5 of the 12 studies testing cerebrolysin in Ischemic Stroke are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cerebrolysin

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing cerebrolysin in Ischemic Stroke, or all of them as a file.
02

Study summary

The study investigates whether Cerebrolysin stabilizes blood-brain barrier integrity in a manner that can be monitored using serum levels of the principal tight junction proteins, e.g., occludin (OCL), claudin-5 (CLN), and zonula occludens-1 (ZO-1), or other molecules known to be involved in BBB degradation, e.g., S100B and whether it protects against hemorrhagic transformation in ischemic stroke patients after reperfusion therapy (i.e. thrombolysis and/or mechanical thrombectomy).

Read the detailed description

Hemorrhagic transformation (HT) of ischemic stroke can be identified in 3-40% of patients. The incidence varies depending on the definition used and the studied population. The severity of HT can be described using clinical and radiological tools and classified as asymptomatic/symptomatic, according to European Cooperative Acute Stroke Study classification and Heidelberg Bleeding Classification. Breakdown of the blood-brain barrier (BBB) is associated with an increased risk of developing a hemorrhagic transformation (HT) of ischemic stroke. In patients who received reperfusion therapy (thrombolysis, mechanical thrombectomy), secondary HT had a negative influence on the clinical course and outcome.

Tight junction (TJ) proteins are important cell adhesion components that stabilize endothelium cells lining and are responsible for maintaining the BBB integrity.

Biomarkers of BBB damage that can be evaluated during the early phases of stroke might be useful for predicting the risk of HT. Such biomarkers could also facilitate the decision of whether to begin thrombolytic therapy in acute ischemic stroke patients. Experimental data support the evidence for protective effect of Cerebrolysin on BBB integrity. Moreover, it diminished and reversed negative effect of recombinant tissue plasminogen activator (rtPA) used as thrombolytic agent on endothelial cells integrity. Cerebrolysin stabilized tight junction proteins expression: occludin, claudin-5 and zona occludens 1 (ZO1). In our previous study we have found that circulating TJs predict HT in ischemic stroke patients. Clinically evident HTs were associated with increased concentrations of occludin and S100B, an increase in the claudin-5/ZO-1 ratio, and a decreased level of vascular endothelial growth factor (VEGF). Claudin-5 levels also correlated with HT occurrence when estimated within 3 hours of stroke onset. The protective effects of Cerebrolysin were already clinically evidenced, however there are no available studies using biomarkers of BBB.

Aim of the study

We aim to investigate whether Cerebrolysin stabilizes BBB integrity in a manner that can be monitored using serum levels of the principal TJ proteins, e.g., occludin (OCL), claudin-5 (CLN), and zonula occludens-1 (ZO-1), or other molecules known to be involved in BBB degradation, e.g., S100B and whether it protects against HT in ischemic stroke patients after reperfusion therapy.

Study design

A prospective longitudinal study will be performed in ischemic stroke patients who:

  1. are included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy - control (group A),
  2. are included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy plus Cerebrolysin (group B)
  3. are not referred to reperfusion therapy nor Cerebrolysin (group C).

All patients with NIHSS score > 8 will receive 30 ml Cerebrolysin in 500 ml of buffered crystalloid solution intravenously initiated within 12 hours from symptoms onset.

Whole blood samples will be withdrawn at the admission, then within 1 to 3 days after stroke onset and at 7th day after stroke onset or when the endpoint will be reached by the patient. Occludin, claudin 5 and ZO-1 concentrations will be analyzed by means of home-made enzyme-linked immunosorbent assay.

Endpoint will include clinical worsening (increase in the NIHSS by > 4 points), radiologically evident hemorrhage or radiologically evident brain edema at control CT performed within 1 to 3 days after stroke onset.

Standard head CT will be performed in all patients at the admission, within 1 to 3 days after stroke onset, after worsening of clinical status and additionally when the differentiation between hemorrhage and contrast staining will be required in thrombectomy patients. Hemorrhagic transformation of ischemic stroke will be classified according to Table 1.

Clinimetric evaluation of all patients will include NIHSS every day for 7 days and at day 30. Modified Rankin scale (mRS) will be evaluated at visit 1,2,3,4 and 5; Barthel index at visit 4 and 5 and Montreal Cognitive Assessment Test at visit 5.

All patents will undergo current American Heart Association Guidelines for the Early Management of Patients with Acute Ischemic Stroke.

Expected results It is expected that Cerebrolysin can stabilize blood-brain barrier in ischemic stroke patients treated with reperfusion therapies via remodelling of tight junction proteins between endothelial cells. Such an effect measured by the levels of circulating tight junction proteins can translate into prevention of hemorrhagic transformation. To summarize, Cerebrolysine can guard blood-brain barrier integrity in ischemic stroke (Cerberus effect).

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Acute Ischemic Stroke
  • blood-brain barrier
  • cerebrolysin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • acute ischemic stroke patients

Exclusion criteria

Exclusion Criteria:

  • no
  • primary or brain tumor
  • brain abscess
  • encephalitis
  • localized inflammation
  • sepsis
  • diseases of central or peripheral nervous system
  • Cerebrolysin / allergy
  • epilepsy
  • severe kidney disease
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
350 participants (estimated)

Study arms

  • No intervention
    Thrombolysis and/or mechanical thrombectomy

    patients included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy - comparator

  • Experimental
    Cerebrolysin

    patients included for reperfusion therapy (intravenous thrombolysis and/or mechanical thrombectomy and treated with Cerebrolysin

    Combination Product: Cerebrolysin

  • No intervention
    No reperfusion therapy / no cerebrolysin

    patients not referred to reperfusion therapy nor Cerebrolysin

Interventions

  • Combination productCerebrolysin

    Intravenous infusion of 30 ml Cerebrolysine in 500 ml of buffered crystalloid solution intravenously initiated within 12 hours from symptoms onset

    Also known as: FPF (Fine Particle Fraction)-1070

06

What researchers measure

Primary outcomes

  1. National Institute of Health Stroke Scale

    National Institute of Health Stroke Scale; score range: 1-42; 1-4 - Minor stroke; 5-15 - Moderate stroke; 16-20 - Moderate to severe stroke; 21-42 - Severe stroke

    Time frame: every day for 7 days after stroke onset

  2. National Institute of Health Stroke Scale

    National Institute of Health Stroke Scale; score range: 1-42; 1-4 - Minor stroke; 5-15 - Moderate stroke; 16-20 - Moderate to severe stroke; 21-42 - Severe stroke

    Time frame: at day 30 after stroke onset

  3. Detection of hemorrhagic transformation [range o:1]

    hemorrhagic transformation on head computerized tomography

    Time frame: within 1 to 3 days after stroke onset, after worsening of clinical status by more than 4 points in NIHSS

  4. Concentration of plasma occludin [ng/mL]

    Occludin is an enzyme (EC 1.6) that oxidizes NADH (Nicotinamide adenine dinucleotide)

    Time frame: at the admission, within 1 to 3 days after stroke onset

  5. Concentration of plasma occludin [ng/mL]

    Occludin is an enzyme (EC 1.6) that oxidizes NADH (Nicotinamide adenine dinucleotide)

    Time frame: at 7th day after stroke onset

  6. Concentration of plasma claudin 5 [ng/mL]

    Claudins are small (20-24/27 kilodalton (kDa)) transmembrane proteins.

    Time frame: at the admission, within 1 to 3 days after stroke onset

  7. Concentration of plasma claudin 5 [ng/mL]

    Claudins are small (20-24/27 kilodalton (kDa)) transmembrane proteins.

    Time frame: at 7th day after stroke onset

  8. Concentration of plasma ZO1 [ng/mL]

    Zonula occludens-1 ZO-1, also known as Tight junction protein-1

    Time frame: at the admission, within 1 to 3 days after stroke onset

  9. Concentration of plasma ZO1 [ng/mL]

    Zonula occludens-1 ZO-1, also known as Tight junction protein-1

    Time frame: at 7th day after stroke onset

Secondary outcomes

  1. Modified Rankin scale [range 0:6]

    Modified Rankin scale; 0-2 - good functional outcome; 3-6 - poor functional outcome

    Time frame: at the admission, within 1 to 3 days after stroke onset

  2. Modified Rankin scale [range 0:6]

    Modified Rankin scale; 0-2 - good functional outcome; 3-6 - poor functional outcome

    Time frame: at 7th day after stroke onset

  3. Modified Rankin scale [range 0:6]

    Modified Rankin scale; 0-2 - good functional outcome; 3-6 - poor functional outcome

    Time frame: at the 30th +/- 5 day after stroke onset

  4. Modified Rankin scale [range 0:6]

    Modified Rankin scale; 0-2 - good functional outcome; 3-6 - poor functional outcome

    Time frame: at 90th +/- 5 day after stroke onset

  5. Barthel Index for Activities of Daily Living (ADL) [range 0:100]

    measures the degree of assistance required by an individual; 0-20 - total dependency, 21-60 - severe dependency, 61-90 - moderate dependency, 91-100 - slight dependency

    Time frame: 30th +/- 5 day after stroke onset

  6. Barthel Index for Activities of Daily Living (ADL) [range 0:100]

    measures the degree of assistance required by an individual; 0-20 - total dependency, 21-60 - severe dependency, 61-90 - moderate dependency, 91-100 - slight dependency

    Time frame: at the 90th +/- 5 day after stroke onset

  7. Death [range 0:1]

    survival measure

    Time frame: within 90 days after stroke onset

  8. Montreal Cognitive Assessment Test [range 0:30]

    the assessment of cognitive functions; 26-30 - normal cognition, 18-25 - mild cognitive impairment, 10-17 - moderate cognitive impairment, \<10 - severe cognitive impairment

    Time frame: at the 90th +/-5 day after stroke onset

07

Study locations

1 of 1 sites recruiting
  • University Hospital
    Poznań, 60-355, Poland
    Recruiting
    • Slawomir Michalak, Prof. · Contactswami@ump.edu.pl · +4861 8691 535
    • Joanna Rybacka-Mossakowska, MD, PhD · Contactjoannarybacka@gmail.com · +4861 8691 458
    • Jacek Namysl, MD · Sub investigator
    • Joanna Rybacka-Mossakowska, MD, PhD · Sub investigator
    • Slawomir Michalak, Prof. · Principal investigator
08

References and documents

Publications

  • Kazmierski R, Michalak S, Wencel-Warot A, Nowinski WL. Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients. Neurology. 2012 Oct 16;79(16):1677-85. doi: 10.1212/WNL.0b013e31826e9a83. Epub 2012 Sep 19. PubMed 22993287 ↗
  • Poljakovic Z, Supe S, Ljevak J, Starcevic K, Peric I, Blazevic N, Krbot-Skoric M, Jovanovic I, Ozretic D. Efficacy and safety of Cerebrolysin after futile recanalisation therapy in patients with severe stroke. Clin Neurol Neurosurg. 2021 Aug;207:106767. doi: 10.1016/j.clineuro.2021.106767. Epub 2021 Jun 18. PubMed 34214867 ↗
  • Teng H, Li C, Zhang Y, Lu M, Chopp M, Zhang ZG, Melcher-Mourgas M, Fleckenstein B. Therapeutic effect of Cerebrolysin on reducing impaired cerebral endothelial cell permeability. Neuroreport. 2021 Mar 24;32(5):359-366. doi: 10.1097/WNR.0000000000001598. PubMed 33661804 ↗
  • Kassner A, Roberts T, Taylor K, Silver F, Mikulis D. Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. AJNR Am J Neuroradiol. 2005 Oct;26(9):2213-7. PubMed 16219824 ↗
  • Zhang Y, Chopp M, Zhang ZG, Zhang Y, Zhang L, Lu M, Zhang T, Winter S, Doppler E, Brandstaetter H, Mahmood A, Xiong Y. Cerebrolysin Reduces Astrogliosis and Axonal Injury and Enhances Neurogenesis in Rats After Closed Head Injury. Neurorehabil Neural Repair. 2019 Jan;33(1):15-26. doi: 10.1177/1545968318809916. Epub 2018 Nov 30. PubMed 30499355 ↗
  • Lang W, Stadler CH, Poljakovic Z, Fleet D; Lyse Study Group. A prospective, randomized, placebo-controlled, double-blind trial about safety and efficacy of combined treatment with alteplase (rt-PA) and Cerebrolysin in acute ischaemic hemispheric stroke. Int J Stroke. 2013 Feb;8(2):95-104. doi: 10.1111/j.1747-4949.2012.00901.x. Epub 2012 Sep 26. PubMed 23009193 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2025, 24 months after the start.

Of 76 non-industry phase 4 interventional studies under Ischemic Stroke, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 42. This study's planned 24 months is below that.

Counting every sponsor, half of 85 studies reached it within 31 months; a quarter within 24 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2023
First posted
Oct 11, 2023
StartActual
Jan 10, 2023
Primary completionEst.
Jan 31, 2025
CompletionEst.
Mar 31, 2025
Last update
Oct 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06078215
Responsible party
Sponsor
First posted
Oct 11, 2023
Start date
Jan 10, 2023
Primary completion
Jan 31, 2025 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
Oct 13, 2023

Study contacts

Slawomir Michalak, Prof.
Contact
swami@ump.edu.pl
+48 61 8691 535
Joanna Rybacka-Mossakowska, MD, PhD
Contact
joannarybacka@gmail.com
+48 61 8691 459
Slawomir Michalak, Prof.
principal investigator · Poznan University of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cerebrolysin

Start the discussion